Cdkn1a
M. musculus
cyclin dependent kinase inhibitor 1A
What the model saw
Gene: Cdkn1a Organism: Mus musculus Known functions: cyclin dependent kinase inhibitor 1A. cyclin-dependent kinase inhibitor 1. cyclin binding. cyclin-dependent protein serine/threonine kinase inhibitor activity. molecular function activator activity. molecular function inhibitor activity. protein binding. protein kinase binding. protein kinase inhibitor activity. protein sequestering activity. protein serine/threonine kinase binding. protein-containing complex binding. ubiquitin protein ligase binding.
View unredacted entry
cyclin dependent kinase inhibitor 1A. cyclin-dependent kinase inhibitor 1. cyclin binding. cyclin-dependent protein serine/threonine kinase inhibitor activity. molecular function activator activity. molecular function inhibitor activity. protein binding. protein kinase binding. protein kinase inhibitor activity. protein sequestering activity. protein serine/threonine kinase binding. protein-containing complex binding. ubiquitin protein ligase binding.
Solver output
Cdkn1a (p21/CIP1) is a canonical cyclin-dependent kinase inhibitor that binds cyclin-CDK complexes (particularly cyclin E/CDK2 and cyclin D/CDK4) to block cell cycle progression, enforcing G1 arrest. This CDK inhibitory activity is a central effector of the p53-p21 senescence pathway, driving cells into stable replicative arrest. Chronic upregulation of p21 in aged tissues promotes the accumulation of senescent cells, which secrete pro-inflammatory SASP factors that damage surrounding tissue and impair stem cell function. While p21 has a short-term tumor-suppressive role, its sustained expression in aging tissues is a net driver of cellular senescence and stem cell exhaustion, reducing regenerative capacity and promoting age-related pathology. Consistent with this, partial reduction of p21 in certain mouse models extends healthspan by limiting senescent cell burden.
GenAge curators classify each gene's normal function as promoting (Pro-Longevity) or opposing (Anti-Longevity) longevity, based on synthesis across studies. Loss-of-function effects can vary from this depending on the manipulation.
Advisor judgment
The model correctly predicted Cdkn1a as anti_longevity with high confidence (0.78). The mechanistic reasoning is excellent and accurate: p21/CIP1 is indeed a CDK inhibitor that enforces cell cycle arrest via the p53-p21 senescence pathway, and its chronic upregulation in aged tissues promotes senescent cell accumulation with SASP, impairing regenerative capacity. The model also correctly notes that reducing p21 in mouse models can extend healthspan. All key pathways identified are relevant and accurate. This is a well-reasoned, correct prediction.
Raw API responses
solver
{
"reasoning": "Cdkn1a (p21/CIP1) is a canonical cyclin-dependent kinase inhibitor that binds cyclin-CDK complexes (particularly cyclin E/CDK2 and cyclin D/CDK4) to block cell cycle progression, enforcing G1 arrest. This CDK inhibitory activity is a central effector of the p53-p21 senescence pathway, driving cells into stable replicative arrest. Chronic upregulation of p21 in aged tissues promotes the accumulation of senescent cells, which secrete pro-inflammatory SASP factors that damage surrounding tissue and impair stem cell function. While p21 has a short-term tumor-suppressive role, its sustained expression in aging tissues is a net driver of cellular senescence and stem cell exhaustion, reducing regenerative capacity and promoting age-related pathology. Consistent with this, partial reduction of p21 in certain mouse models extends healthspan by limiting senescent cell burden.",
"confidence": 0.78,
"key_pathways": [
"p53-p21 senescence pathway",
"cyclin-CDK cell cycle regulation",
"senescence-associated secretory phenotype (SASP)"
],
"mechanism_class": "cellular_senescence",
"longevity_influence": "anti_longevity"
}advisor
{
"notes": "The model correctly predicted Cdkn1a as anti_longevity with high confidence (0.78). The mechanistic reasoning is excellent and accurate: p21/CIP1 is indeed a CDK inhibitor that enforces cell cycle arrest via the p53-p21 senescence pathway, and its chronic upregulation in aged tissues promotes senescent cell accumulation with SASP, impairing regenerative capacity. The model also correctly notes that reducing p21 in mouse models can extend healthspan. All key pathways identified are relevant and accurate. This is a well-reasoned, correct prediction.",
"failure_mode": "correct",
"answer_correct": true,
"mechanism_correct": true,
"reasoning_quality": 5,
"ground_truth_questionable": false
}